USE OF LOW-DOSE IL-2 TO EXPAND ENDOGENOUS REGULATORY T CELLS AND ACHIEVE TRANSPLANTATION TOLERANCE
Lead Research Organisation:
King's College London
Department Name: Transplantation Immunology & Mucosal Bio
Abstract
A population of immune cells, called regulatory T cells or Tregs, have been shown in experimental animal models to regulate the immune system and to play a central role in preventing organ rejection and in controlling autoimmune and inflammatory diseases. In animal models of transplantation, Tregs are key to induce immunological tolerance, a situation in which the transplanted organ is indefinitely accepted in the absence of anti-rejection medication. The use of IL-2 at low doses has been shown to selectively and safely increase the number of Tregs in humans, but whether this can be used to induce tolerance in transplanted patients has never been investigated. Liver transplantation is an optimal clinical setting to do so, given that there are evidences indicating that transplantation tolerance can spontaneously occur in these patients (albeit only many years after transplantation), and that liver transplantation is the only solid organ transplantation setting in which it is safe to investigate the development of tolerance by intentionally discontinuing all anti-rejection medications.
Our hypothesis is that administration of a short course of low-dose IL-2 will transiently expand the number of Tregs and allow for the permanent discontinuation of anti-rejection medication. In the current project we propose to conduct a clinical study in which liver transplant recipients who have a very low probability of achieving tolerance spontaneously will receive daily injections of IL-2 during the period of time when their anti-rejection medication is gradually withdrawn. Patients will be carefully studied to investigate the following:
1) Whether IL-2 is efficacious in expanding the number of Tregs in liver transplant patients.
2) Whether the expansion of Tregs in the circulation and/or the liver facilitates the successful discontinuation of anti-rejection medication.
3) What are the effects of an increased number of Tregs in the immune system of a transplanted patient.
Ultimately, the project will serve to clarify whether donor-specific Tregs are essential to establish transplantation tolerance, and the extent to which low-dose IL-2 is an effective strategy to promote this phenomenon. This will have implications for a number of other inflammatory diseases, and will open the door to future clinical trials in which low-dose IL-2 could used in combination with other tolerance-promoting medications.
Our hypothesis is that administration of a short course of low-dose IL-2 will transiently expand the number of Tregs and allow for the permanent discontinuation of anti-rejection medication. In the current project we propose to conduct a clinical study in which liver transplant recipients who have a very low probability of achieving tolerance spontaneously will receive daily injections of IL-2 during the period of time when their anti-rejection medication is gradually withdrawn. Patients will be carefully studied to investigate the following:
1) Whether IL-2 is efficacious in expanding the number of Tregs in liver transplant patients.
2) Whether the expansion of Tregs in the circulation and/or the liver facilitates the successful discontinuation of anti-rejection medication.
3) What are the effects of an increased number of Tregs in the immune system of a transplanted patient.
Ultimately, the project will serve to clarify whether donor-specific Tregs are essential to establish transplantation tolerance, and the extent to which low-dose IL-2 is an effective strategy to promote this phenomenon. This will have implications for a number of other inflammatory diseases, and will open the door to future clinical trials in which low-dose IL-2 could used in combination with other tolerance-promoting medications.
Technical Summary
Transplantation remains the most successful treatment for end-stage organ failure, but the need to administer life-long immunosuppression (IS) to prevent rejection limits patient survival. Liver transplantation is the only transplantation setting in which a sizeable proportion of patients spontaneously develop "operational tolerance", a phenomenon defined by the maintenance of stable graft function in the absence of destructive immune responses without the need of IS. Unfortunately this phenomenon preferentially develops in elderly recipients and several years after transplantation. To maximize the benefit derived from IS discontinuation there is a need to find strategies to intentionally induce tolerance in young recipients in whom accumulated IS toxicity has not yet occurred. Our studies have revealed that successful IS discontinuation is associated with a transient intra-graft immune regulatory response with preferential accumulation of regulatory T cells (Tregs). This suggests that short-term enhancement of Treg numbers and/or function at the time of IS withdrawal may facilitate the acquisition of tolerance in patients who are not predisposed to spontaneously develop it. IL-2 is a cytokine that is essential for the optimal development, survival and function of Tregs. Several clinical studies have shown that low-dose IL-2 preferentially expands Tregs and is safe and efficacious in patients with autoimmunity or GVHD. In these studies, Treg frequency increased up to 2 to 8-fold without significant changes in the number of effector T cells. Our objective is to investigate if administration of a short-course of low-dose IL-2 to liver transplant recipients facilitates the discontinuation of IS. We propose to conduct a prospective, phase II, efficacy, single-arm clinical trial in which liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their IS medication.
Planned Impact
The current project will provide fundamental information on how regulatory T cells (Tregs) exert their suppressive function in the setting of liver transplantation, and will answer the question of whether Tregs play a central role in the establishment of immunological tolerance in humans, and the extent to which low-dose IL-2 is efficacious in harnessing Tregs towards this goal. This information will have direct implications for the future development of Treg immunotherapy, which has the potential to be of great benefit to patients with organ transplantation or with chronic inflammatory disorders requiring long-term immunosuppressive therapy, as it may allow for a reduction or cessation in the amount of immunosuppression required with the consequent improvement in immunosuppression-related morbidity and mortality.
The scope of the project goes beyond the field of transplantation, however, as Tregs act as mediators or modulators in virtually all inflammatory responses. A deeper understanding on how human Tregs function in vivo will provide clues as to the optimal conditions required to promote Treg function, or, alternatively, point out to novel strategies to reduce their effects.
Patients and the wide academic community will therefore be the major beneficiaries. In addition, given the commercial potential of Treg therapies, the cell therapy biotech industry may be an additional beneficiary, which is an area we are actively exploring through our collaboration with the UK Cell Therapy Catapult.
The scope of the project goes beyond the field of transplantation, however, as Tregs act as mediators or modulators in virtually all inflammatory responses. A deeper understanding on how human Tregs function in vivo will provide clues as to the optimal conditions required to promote Treg function, or, alternatively, point out to novel strategies to reduce their effects.
Patients and the wide academic community will therefore be the major beneficiaries. In addition, given the commercial potential of Treg therapies, the cell therapy biotech industry may be an additional beneficiary, which is an area we are actively exploring through our collaboration with the UK Cell Therapy Catapult.
Publications
Feng S
(2019)
Pediatric Hepatology and Liver Transplantation
Lim T
(2023)
Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans
in Journal of Hepatology
Lim TY
(2018)
Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis.
in Hepatology (Baltimore, Md.)
Mastoridis S
(2017)
Immunotolerance in Liver Transplantation.
in Seminars in liver disease
Ratnasothy K
(2019)
IL-2 therapy preferentially expands adoptively transferred donor-specific Tregs improving skin allograft survival.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Sánchez-Fueyo A
(2021)
On minor histocompatibility antigens, mixed chimerism, and transplantation tolerance.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Sánchez-Fueyo A
(2020)
Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Thomson AW
(2020)
Understanding, predicting and achieving liver transplant tolerance: from bench to bedside.
in Nature reviews. Gastroenterology & hepatology
Whitehouse G
(2017)
IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors
in Proceedings of the National Academy of Sciences
Whitehouse GP
(2017)
Regulatory T-cell therapy in liver transplantation.
in Transplant international : official journal of the European Society for Organ Transplantation
Description | Immune Tolerance Network |
Amount | $30,000 (USD) |
Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
Sector | Public |
Country | United States |
Start | 02/2017 |
End | 01/2018 |
Description | Liver Specific Tregs |
Amount | £97,000 (GBP) |
Funding ID | Developing liver-specific engineered regulatory T cells to treat inflammatory liver disorders and to promote liver repair |
Organisation | King's College London |
Department | London Advanced Therapies |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2020 |
Description | MRC DPFS |
Amount | £1,007,574 (GBP) |
Funding ID | MR/N019334/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2017 |
End | 05/2021 |
Description | Optimization of the potency, specificity and survival properties of engineered regulatory T cells to treat inflammatory liver diseases |
Amount | £198,505 (GBP) |
Organisation | Rosetrees Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2021 |
End | 11/2024 |
Description | Regulatory T cell treatment for the prevention of CAV in children receiving heart transplant |
Amount | £401,383 (GBP) |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2022 |
End | 12/2024 |
Description | ORGANTRANS H2020 EU Consortium: 'Organ 3D printing for liver regenerative medicine' |
Organisation | Leibniz Institute for Interactive Materials |
Country | Germany |
Sector | Private |
PI Contribution | My research group's contribution is to define how the inflammatory microenvironment present in the setting of liver failure influences liver organoid viability. |
Collaborator Contribution | The aims of the project are to replace liver transplantation for end-stage liver failure patients through the development of a liver tissue 3D printing platform. The project will cover the entire development cycle from cell source and tissue engineering through the trials allowing for early adoption of its results in clinical practice. Importantly, this research will create novel technologies that can be applied to other organ systems in regenerative medicine. |
Impact | This is a multidisciplinary collaboration with an overall budget of € 6,301,156.25 involving partners in Germany, Netherlands, Czechia, Belgium, and UK with expertise in liver cell biology, organoid generation, liver inflammation, biogengineering and commercial. |
Start Year | 2020 |
Description | ORGANTRANS H2020 EU Consortium: 'Organ 3D printing for liver regenerative medicine' |
Organisation | Swiss Center for Electronics and Microtechnology |
Country | Switzerland |
Sector | Charity/Non Profit |
PI Contribution | My research group's contribution is to define how the inflammatory microenvironment present in the setting of liver failure influences liver organoid viability. |
Collaborator Contribution | The aims of the project are to replace liver transplantation for end-stage liver failure patients through the development of a liver tissue 3D printing platform. The project will cover the entire development cycle from cell source and tissue engineering through the trials allowing for early adoption of its results in clinical practice. Importantly, this research will create novel technologies that can be applied to other organ systems in regenerative medicine. |
Impact | This is a multidisciplinary collaboration with an overall budget of € 6,301,156.25 involving partners in Germany, Netherlands, Czechia, Belgium, and UK with expertise in liver cell biology, organoid generation, liver inflammation, biogengineering and commercial. |
Start Year | 2020 |
Description | ORGANTRANS H2020 EU Consortium: 'Organ 3D printing for liver regenerative medicine' |
Organisation | Utrecht University |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | My research group's contribution is to define how the inflammatory microenvironment present in the setting of liver failure influences liver organoid viability. |
Collaborator Contribution | The aims of the project are to replace liver transplantation for end-stage liver failure patients through the development of a liver tissue 3D printing platform. The project will cover the entire development cycle from cell source and tissue engineering through the trials allowing for early adoption of its results in clinical practice. Importantly, this research will create novel technologies that can be applied to other organ systems in regenerative medicine. |
Impact | This is a multidisciplinary collaboration with an overall budget of € 6,301,156.25 involving partners in Germany, Netherlands, Czechia, Belgium, and UK with expertise in liver cell biology, organoid generation, liver inflammation, biogengineering and commercial. |
Start Year | 2020 |
Title | LITE trial |
Description | The LITE trial's goal was to investigate the biological activity and clinical efficacy of low-dose interleukin-2 (Proleukin) in expanding endogenous regulatory T cells in liver transplant recipients and inducing liver allograft tolerance. The trial was supported by a MRC DPFS grant. The trial was terminated due to safety concerns. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2019 |
Development Status | Closed |
Clinical Trial? | Yes |
Impact | The trial has served to defined the therapeutic window of low-dose interleukin-2 in the setting of solid organ transplantation. |
URL | https://clinicaltrials.gov/show/NCT02949492 |
Title | LITE trial: Low-dose IL-2 to expand endogenous Tregs and achieve tolerance in liver transplantation |
Description | The purpose of the trial is to assess the capacity of low doses of IL-2 to expand endogenous regulatory T cells and promote the development of operational tolerance following liver transplantation. Phase IV, open-label, activity, safety and efficacy, prospective, single-arm clinical trial in which liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication. Based on the IL-2 activity and safety after 1 month of treatment in the first 8 participants, the study will continue or it will terminate. In participants with a satisfactory increase in circulating Tregs after 1 month of IL-2 therapy, treatment will be maintained for 5 additional months while immunosuppressive drugs are gradually discontinued over a 3 month period. Efficacy will be determined by assessing the proportion of subjects who achieve successful immunosuppression withdrawal defined by the absence of rejection and a rejection free biopsy at 1 year following discontinuation of immunosuppression. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2017 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | The development process of the trial has allowed the set up a medication circuit to manufacture and administer IL-2 to outpatient liver transplant recipients, and it has included a pilot study in which IL-2 was administered to patients with autoimmune liver disease. |
URL | https://clinicaltrials.gov/show/NCT02949492 |
Company Name | QUELL THERAPEUTICS LIMITED |
Description | Quell is a spin-off whose objective is to develop engineered regulatory T cells to treat transplant rejection, autoimmunity and inflammatory diseases. Quell was founded in March 2019 in partnership with scientists from King's College London, University College London and Hannover Medical School. Quell was founded with initial series A financing, led by Syncona Ltd who committed £34M with a further £1M contributed by UCL Technology Fund. |
Year Established | 2019 |
Impact | Quell currently has 12 FTE scientific posts within an overall staff of 22 people. |
Website | https://quell-tx.com |
Description | 4th International Workshop on Clinical Tolerance |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Scientific talk describing the outcome of our clinical trials in live transplant tolerance |
Year(s) Of Engagement Activity | 2019 |
Description | American Transplant Congress 2019 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Dissemination of study results among transplantation medical professionals |
Year(s) Of Engagement Activity | 2019 |
Description | Patient group workshop (LISTEN group Kings College Hospital) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | The LISTEN group is a support group for liver transplant patients at Kings College Hospital. I provide yearly workshops to discuss ongoing research in liver transplantation consisting in a short presentation followed by a debate. |
Year(s) Of Engagement Activity | 2014,2015,2016,2017 |